# Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation

> **NCT07699796** · PHASE4 · COMPLETED · sponsor: **Heart, Artery, and Vein Center of Fresno** · enrollment: 564 (actual)

## Conditions studied

- Venous Thrombosis Deep (Limbs)
- Venous Insufficiency (Chronic)(Peripheral)
- Varicose Veins Leg
- Venous Thrombosis

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT07699796
- **Lead sponsor:** Heart, Artery, and Vein Center of Fresno
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-06
- **Primary completion:** 2020-11-04
- **Final completion:** 2021-06-15
- **Target enrollment:** 564 (ACTUAL)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07699796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07699796, "Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07699796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*